[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503756":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":18,"locations":28,"responsibleParty":44,"collaborators":7,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":7,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":7,"enrollmentInfo":55,"targetDuration":7,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":7,"overallStatus":31,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Gruppo Italiano Malattie EMatologiche dell'Adulto","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","Biological characterization of AML with MECOM or atypical 3q26 rearrangements","Peripheral blood and bone marrow withdrawal",[14],{"name":15,"affiliation":16,"role":17},"Giovanni Roti","Department of Medicine and Surgery, University of Parma, Parma","PRINCIPAL_INVESTIGATOR",[19,24],{"name":20,"role":21,"phone":22,"phoneExt":7,"email":23},"Paola Fazi","CONTACT","0670390528","p.fazi@gimema.it",{"name":25,"role":21,"phone":26,"phoneExt":7,"email":27},"Enrico Crea","0670390514","e.crea@gimema.it",[29],{"facility":30,"status":31,"city":32,"state":7,"zip":7,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Ematologia","RECRUITING","Piacenza","Italy","IT",{"type":36,"coordinates":37},"Point",[38,39],9.69342,45.05242,{"lat":39,"lon":38},[42],{"name":43,"role":21,"phone":7,"phoneExt":7,"email":7},"Vallisa",{"type":45,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100503756","novel-approaches-to-target-mecomevi1-in-aml-100503756",false,"NCT05839392","Novel Approaches to Target MECOM\u002FEVI1 in AML","Novel Approaches to Target MECOM\u002FEVI1 in Acute Myeloid Leukemia","Inclusion Criteria:\n\n* AML with MECOM or atypical 3q26 rearrangements.\n* Age ≥18.\n* Signed written informed consent according to ICH\u002FEU\u002FGCP and national local laws.\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":56,"type":57},24,"ESTIMATED","INTERVENTIONAL",[60],"NA","This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.",[63],"AML, Adult","2023-12-22",{"date":66,"type":67},"2023-12-29","ACTUAL",{"date":69,"type":67},"2023-12-13",{"date":71,"type":57},"2026-12",{"name":5,"class":6},1]